[1]
|
Rozati, S., Naef, L., Levesque, M.P., French, L.E. and Dummer, R. (2012) Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy. Journal of Immunotherapy, 36, 52-56.
|
[2]
|
Inman, B.A., Harrison, M.R. and George, D.J. (2012) Novel immunotherapeutic strategies in development for renal cell carcinoma. European Urology, in Press.
doi:10.1016/j.eururo.2012.10.006
|
[3]
|
Coppin, C., Porzsolt, F., Awa, A., Kumpf, J., Coldman, A. and Wilt, T. (25 January 2005) Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews, Article ID: CD001425.
|
[4]
|
Ruiz-Delgado, G.J., Tarin-Arzaga, L.C., Alarcon-Urdaneta, C., Calderon-Garcia, J., Gomez-Almaguer, D. and Ruiz-Arguelles, G.J. (2012) Treatment of hairy cell leukemia: Long-term results in a developing country. Hematology, 17, 140-143.
doi:10.1179/102453312X13376952196331
|
[5]
|
Regnier-Rosencher, E., Guillot, B. and Dupin, N. (2012) Treatments for classic Kaposi sarcoma: A systematic review of the literature. Journal of the American Academy of Dermatology, 68, 313-331.
|
[6]
|
Chen, Y.S., Yi, W. and Jiang, K. (2012) Effects of antiviral nucleotide/nucleoside analogues and interferon on hepatitis B virus-related liver cirrhosis: A meta-analysis. Zhonghua Gan Zang Bing Za Zhi, 20, 811-816.
|
[7]
|
Chayama, K., Hayes, C.N., Ohishi, W. and Kawakami, Y. (2012) Treatment of chronic hepatitis C virus infection in Japan: Update on therapy and guidelines. Journal of Gastroenterology, 48, 1-12.
|
[8]
|
Enudi, W. and Udolu, O.J. (2009) Neuropsychiatric complications associated with interferon-alpha-2b treatment of malignant melanoma. African Journal of Psychiatry (Johannesbg), 12, 227-228.
|
[9]
|
McNutt, M.D., Liu, S., Manatunga, A., Royster, E.B., Raison, C.L., Woolwine, B.J., Demetrashvili, M.F., Miller, A.H. and Musselman, D.L. (2012) Neurobehavioral effects of interferon-alpha in patients with hepatitis-C: Symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology, 37, 1444-1454.
doi:10.1038/npp.2011.330
|
[10]
|
Malaguarnera, M., Vicari, E., Calogero, A., Cammalleri, L., Di, F.I., Gargante, M.P., Pennisi, G., Risino, C., Ranno, S. and Rampello, L. (2008) Sexual dysfunction in chronic hepatitis C virus patients treated with interferon alpha and ribavirin. Journal of Interferon & Cytokine Research, 28, 603-609. doi:10.1089/jir.2008.0021
|
[11]
|
Dove, L.M., Rosen, R.C., Ramcharran, D., Wahed, A.S., Belle, S.H., Brown, R.S. and Hoofnagle, J.H. (2009) Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology, 137, 873-884.
|
[12]
|
Argiris, A., Agarwala, S.S., Karamouzis, M.V., Burmeister, L.A. and Carty, S.E. (2008) A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs, 26, 183-188.
doi:10.1007/s10637-007-9091-2
|
[13]
|
Kose, S., Gozaydin, A., Akkoclu, G. and Ece, G. (2012) Chronic hepatitis B with type I diabetes mellitus and autoimmune thyroiditis development during interferon alpha therapy. The Journal of Infection in Developing Countries, 6, 364-368.
|
[14]
|
Andrade, L.J., Atta, A.M., Atta, M.L., Mangabeira, C.N. and Parana, R. (2011) Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy. Brazilian Journal of Infectious Diseases, 15, 377-381. doi:10.1590/S1413-86702011000400013
|
[15]
|
Menconi, F., Hasham, A. and Tomer, Y. (2011) Environmental triggers of thyroiditis: hepatitis C and interferonalpha. Journal of Endocrinological Investigation, 34, 78-84
|
[16]
|
Fentiman, I.S., Thomas, B.S., Balkwill, F.R., Rubens, R.D. and Hayward, J.L. (1985) Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet, 1, 1166.
|
[17]
|
Oppenheim, Y., Kim, G., Ban, Y., Unger, P., Concepcion, E., Ando, T. and Tomer, Y. (2003) The effects of alpha interferon on the development of autoimmune thyroiditis in the NOD H2h4 mouse. Clinical and Developmental Immunology, 10, 161-165.
doi:10.1080/10446670310001642177
|
[18]
|
Tomer, Y. and Menconi, F. (2009) Interferon induced thyroiditis. Best Practice & Research: Clinical Endocrinology & Metabolism, 23, 703-712.
doi:10.1016/j.beem.2009.07.004
|
[19]
|
Buck, H.W., Jr. (2010) Genital warts. Clinical Evidence, 2010, PMC3217761.
|
[20]
|
Yang, J., Pu, Y.G., Zeng, Z.M., Yu, Z.J., Huang, N. and Deng, Q.W. (2009) Interferon for the treatment of genital warts: A systematic review. BMC Infectious Diseases, 9, 156. doi:10.1186/1471-2334-9-156
|
[21]
|
Mynbaev, O.A. and Eliseeva, M.Y. (2011) The scoring scale of researches’ cogency devoted to efficacy of immunomodulators from the position of evidence-based medicine. Siberian Journal of Oncology, N6, 70-73. (Rus.)
|
[22]
|
Mynbaev, O.A., Eliseeva, M.Y. and Chernov, A.V. (2011) Lapsus creativus or sciolistic daydreaming (Manilovshina). Z Turbotoyu pro Zhinku, 3, 32-34. (Rus.)
|
[23]
|
Ward, D.L. and Bing-You, R.G. (2001) Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: Screening and monitoring recommendations. Endocrine Practice, 7, 52-58.
|
[24]
|
Caraccio, N., Giannini, R., Cuccato, S., Faviana, P., Berti, P., Galleri, D., Dardano, A., Basolo, F., Ferrannini, E. and Monzani, F. (2005) Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. The Journal of Clinical Endocrinology & Metabolism, 90, 1156-1162. doi:10.1210/jc.2004-1173
|
[25]
|
Caraccio, N., Cuccato, S., Pratesi, F., Dardano, A., Ursino, S., Chimenti, D., Boldrini, L., Materazzi, G., Migliorini, P. and Monzani, F. (2009) Effect of type I interferon(s) on cell viability and apoptosis in primary human thyrocyte cultures. Thyroid, 19, 149-155.
doi:10.1089/thy.2008.0290
|
[26]
|
Akeno, N., Smith, E.P., Stefan, M., Huber, A.K., Zhang, W., Keddache, M. and omer, Y. (2011) IFN-alpha mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. The Journal of Immunology, 186, 4693-4706.
doi:10.4049/jimmunol.1002631
|
[27]
|
Simin, M., Brok, J., Stimac, D., Gluud, C. and Gluud, L.L. (2007) Cochrane systematic review: Pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Alimentary Pharmacology & Therapeutics, 25, 1153-1162. doi:10.1111/j.1365-2036.2007.03294.x
|
[28]
|
Minami, T., Kishikawa, T., Sato, M., Tateishi, R., Yoshida, H. and Koike, K. (2012) Meta-analysis: Mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. Journal of Gastroenterology, 48, 254-268.
|
[29]
|
Tran, H.A., Jones, T.L., Ianna, E.A., Foy, A. and Reeves, G.E. (27 November 2012) Thyroid disease in chronic hepatitis C infection treated with combination interferonalpha and ribavirin: Management strategies and future perspective. Endocrine Practice, 1-33.
|